Apoptosis Affecting Patents (Class 514/18.9)
-
Patent number: 12264204Abstract: The present disclosure relates to a method for producing a silk-derived peptide. The method for producing a silk-derived peptide may comprise steps of: dissolving silk fibroin; hydrolyzing the dissolved silk fibroin by treatment with an enzyme mixture comprising a first protease, which comprises bromelain, and a second protease comprising any one selected from the group consisting of Flavourzyme, Protamex, neutrase, Veron W, Sumizyme, zingibn, calpain, protease NP, validase, and mixtures thereof; and removing the proteases.Type: GrantFiled: September 16, 2020Date of Patent: April 1, 2025Assignee: NATURESENSE CO., LTD.Inventor: Ji Won Lee
-
Patent number: 12257341Abstract: The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).Type: GrantFiled: May 29, 2020Date of Patent: March 25, 2025Assignee: LG CHEM, LTD.Inventors: Sung Won Kim, Jae Uk Baek, Hyun Seo Park, Myung Won Jin, Jung Gyu Park, Bok Tae Kim, Sei Hyun Choi
-
Patent number: 12178840Abstract: Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT).Type: GrantFiled: September 27, 2021Date of Patent: December 31, 2024Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.Inventors: Annette Khaled, Jesus Manuel Perez, Rania Bassiouni
-
Patent number: 12168006Abstract: The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors.Type: GrantFiled: November 28, 2022Date of Patent: December 17, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Jessie Peh, Matthew Boudreau
-
Patent number: 12122786Abstract: The described compounds are of the class of cyclic nucleotides, both mono- and di-nucleotides, which play diverse roles in the prokaryotes and eukaryotes having the general formula which inhibit phosphodiesterases that inhibit cyclic mononucleotide or dinucleotides and/or both mononucleotide and dinucleotide. These compounds have potential diverse applications as antiviral, antibacterial, anti-inflammatory and anticancer agents, including cancer immunotherapy. Pharmaceutical compositions and methods for treating those kinase related diseases are within the scope of this invention.Type: GrantFiled: December 16, 2021Date of Patent: October 22, 2024Assignee: Purdue Research FoundationInventors: Herman O. Sintim, George Naclerio, Caroline Karanja
-
Patent number: 12065511Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: GrantFiled: March 13, 2020Date of Patent: August 20, 2024Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
-
Patent number: 12059474Abstract: Methods for producing and screening for antibodies that specifically bind to glycosylated immune checkpoint proteins (ICPs) relative to non-glycosylated ICPs are provided. Such antibodies recognize specific epitopes of glycosylated ICPs and can prevent or block the binding of a glycosylated ICP with its ligand, such as another ICP, and can inhibit the interactions between the two proteins that can lead to immunosuppression, as exemplified by the human PD-L1/PD-1 interaction. By way of specific example, human PD-L1 and PD-1 polypeptides comprising glycosylated amino acid residues within their extracellular domains are provided for generating anti-glycosylated PD-L1 or anti-glycosylated PD-1 antibodies that specifically bind PD-L1 or PD-1, respectively, and inhibit the PD-L1/PD-1 interaction. The antibodies produced and selected by the methods are especially useful as cancer therapeutics for disrupting, blocking, or neutralizing the ICP system and specific ICP interactions therein.Type: GrantFiled: March 24, 2017Date of Patent: August 13, 2024Assignees: STCUBE & CO., INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Mien-Chie Hung
-
Patent number: 12043621Abstract: The technology described herein is directed to IL-4 and/or IL-13 inhibitors and uses thereof.Type: GrantFiled: March 19, 2021Date of Patent: July 23, 2024Assignees: Trustees of Boston University, Massachusetts Institute of TechnologyInventors: Arturo Vegas, Sean Quinnell, Daniel Sheehy, Kelly Tan, Luke Ceo, Stephen Thomas Nestor, Angela Nicole Koehler, Becky Leifer, Shelby Doyle
-
Patent number: 11999776Abstract: The present invention provides a novel IGFR-like receptor 2 and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of cancer or diabetes.Type: GrantFiled: August 25, 2021Date of Patent: June 4, 2024Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Heiko Lickert, Ünal Coskun, Sarah Homberg
-
Patent number: 11970489Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones derivatives and their use as larvicidal agents.Type: GrantFiled: October 23, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Katharigatta N. Venugopala, Osama I. Alwassil, Pran Kishore Deb, Rashmi Venugopala, Priya R. Kadam, Yadav D. Bodke, Vijaykumar Uppar
-
Patent number: 11971402Abstract: The present invention relates to methods and kits for prognosing, treating, and managing treatment of cancer in a subject. The methods involve selecting a subject having cancer and obtaining, from the selected subject, a sample containing exosomes or an S100 molecule containing sample. The exosomes or S100 molecule containing sample, respectively, are then contacted with one or more reagents suitable to detect higher or lower levels or the presence or absence of one or more integrins on said exosomes or higher or lower levels or the presence or absence of one or more S100 molecules in the S100 molecule containing sample. The cancer is then prognosed, treatment is administered, or treatment is managed.Type: GrantFiled: April 25, 2016Date of Patent: April 30, 2024Assignee: CORNELL UNIVERSITYInventors: David C. Lyden, Ayuko Hoshino, Bruno Da Silva
-
Patent number: 11952402Abstract: A recombinant protein includes a TRAIL domain and an IgG binding domain IgBD. In the recombinant protein, IgBD can be fused at the N-terminus or C-terminus of the TRAIL domain. The anti-tumor effect of the recombinant protein after binding to endogenous or exogenous IgG is significantly stronger than that of TRAIL, and can be used in the treatment of cell proliferative diseases with high expression of death receptors.Type: GrantFiled: August 10, 2020Date of Patent: April 9, 2024Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITYInventors: Xiaofeng Lu, Hao Yang, Ze Tao, Jingqiu Cheng
-
Patent number: 11932675Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.Type: GrantFiled: October 9, 2020Date of Patent: March 19, 2024Assignees: GENENTECH, INC., XENCOR, INC.Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
-
Patent number: 11873281Abstract: A conjugate of a potent cytotoxic agent with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.Type: GrantFiled: February 5, 2020Date of Patent: January 16, 2024Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventors: R. Yongxin Zhao, Yue Zhang, Yourang Ma
-
Patent number: 11834451Abstract: This invention is in the field of medicinal chemistry and relates to a new class of small-molecules having a pyrazolopyridine (or similar) structure (e.g., Formula I) which function as inhibitors of the viral protein 2C protein activity and/or expression, and which function as therapeutics for the treatment of viral infection characterized with viral protein 2C activity and/or expression (e.g., non-polio enterovirus infection) (e.g., enterovirus D68 (EV-D68) infection, enterovirus A71 (EV-A71) infection, and coxsackievirus B3 (CVB3) infection.Type: GrantFiled: March 28, 2022Date of Patent: December 5, 2023Assignee: Arizona Board of Regents on Behalf of the University of ArizonaInventors: Jun Wang, Naoya Kitamura
-
Patent number: 11833174Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.Type: GrantFiled: September 17, 2020Date of Patent: December 5, 2023Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Chengfei Pu, Dongqi Chen, Wei Ding
-
Patent number: 11767294Abstract: A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.Type: GrantFiled: May 9, 2019Date of Patent: September 26, 2023Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventors: R. Yongxin Zhao, Yue Zhang, Yourang Ma
-
Patent number: 11731964Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.Type: GrantFiled: March 29, 2019Date of Patent: August 22, 2023Assignee: Purdue Research FoundationInventors: Herman O. Sintim, Mohamed Seleem, Clement Opoku-Temeng, Haroon Taj Mohammad, George Naclerio
-
Patent number: 11717635Abstract: The invention relates to an inhalable gaseous medicament containing argon gas for use in combination with a mechanical thrombectomy for treating, reducing or resorbing brain lesions subsequent to an ischaemic stroke in an individual. Preferably, the proportion by volume of argon is between 30 and 79%. The mechanical thrombectomy can be accompanied by a drug-based thrombolysis to dissolve the clot and to thin the blood of the patient.Type: GrantFiled: September 11, 2020Date of Patent: August 8, 2023Assignees: L'Air Liquide, SociétéAnonyme pour l'Etude et l'Exploitation des Procédés Georges Claude, Aix-Marseille Université, Centre National de la Recherche ScientifiqueInventors: Géraldine Farjot, Catherine Billoet, Lionel Velly, Thomas Brochier
-
Patent number: 11672861Abstract: Biofunctionalized nanocomposites comprised of a core nanoparticle formed of Prussian blue materials, a shell obtained by partially or completely encapsulating the Prussian blue core with a biocompatible coating, and at least one biomolecule attached to, or absorbed to, the biocompatible coating and uses thereof.Type: GrantFiled: March 19, 2019Date of Patent: June 13, 2023Assignee: The George Washington UniversityInventors: Rohan Fernandes, Elizabeth Sweeney, Juliana Cano-Mejia
-
Patent number: 11628203Abstract: A pharmaceutical composition contains Nkx3.2 and a fragment thereof as an active ingredient. The Nkx3.2 and/or the fragment thereof inhibit(s) retinal degeneration caused by oxidative stress and preserve(s) visual function. In addition, the Nkx3.2 and/or the fragment thereof inhibit(s) cell death due to the oxidative stress of retinal pigment epithelial cells and inhibit(s) choroidal neovascularization and retinal edema. Therefore, a composition containing the Nkx3.2 and/or the fragment thereof as active ingredient(s) can be effectively used for preventing or treating retinal dystrophies or macular degeneration.Type: GrantFiled: October 19, 2018Date of Patent: April 18, 2023Assignee: ICM CO., LTD.Inventors: Dae-Won Kim, Young-Na Yum, Heui-Young Ryu, Da-Un Jeong, Seung-Won Choi
-
Patent number: 11623918Abstract: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: November 17, 2021Date of Patent: April 11, 2023Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as Represented by the Department of Veterans AffairsInventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
-
Patent number: 11617738Abstract: The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7 (USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer, and immunological disorders. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases mediated by malfunction of USP7, in mammals using compounds disclosed herein.Type: GrantFiled: March 12, 2021Date of Patent: April 4, 2023Assignee: Purdue Research FoundationInventors: Antonella Pepe, Andrew Mesecar
-
Patent number: 11458172Abstract: Provided is a nucleic acid system introduced into a bacterial strain to generate a genetically engineered bacterial strain that grows in solid tumors but does not grow in non-tumor tissues, the nucleic acid system comprising: a first DNA fragment that encodes a toxin gene that expresses a toxin that kills the genetically engineered bacterial strain; a second DNA fragment that encodes an antidote gene that expresses an antidote that negates the toxin; a first promotor that controls transcription of the antidote gene, such that glucose represses the transcription of the antidote gene; and a first constitutive promoter that causes constitutive expression of the toxin gene; wherein the second DNA fragment is transcribed in the solid tumors but not transcribed in the non-tumor tissues.Type: GrantFiled: September 8, 2017Date of Patent: October 4, 2022Assignee: New Portal LimitedInventor: Ye Jin
-
Patent number: 11371061Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.Type: GrantFiled: November 30, 2016Date of Patent: June 28, 2022Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNEInventors: Saliha Majdoul, David Fenard
-
Patent number: 11229641Abstract: Compounds and pharmaceutical compositions thereof for inducing apoptosis in a cell expressing Bcl-2 and IP3R and their use in a method for treating neoplastic disorders in a subject.Type: GrantFiled: February 6, 2017Date of Patent: January 25, 2022Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Clark Distelhorst
-
Patent number: 11078246Abstract: This disclosure features stapled peptide inhibitors (e.g., cysteine-reactive stapled peptides) of the anti-apoptotic protein, BFL-1, and methods of using same in the treatment of BFL-1 expressing cancers.Type: GrantFiled: August 26, 2016Date of Patent: August 3, 2021Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory H. Bird
-
Patent number: 10954278Abstract: Described are methods and associated uses for the treatment of resorptive bone disease using peptides comprising all of part of the C-terminal portion of soricidin. Also described are methods and associated uses for inhibiting osteoclast activity and/or bone resorption using the peptides.Type: GrantFiled: November 2, 2016Date of Patent: March 23, 2021Assignee: University of New BrunswickInventors: Alli Murugesan, Anthony Reiman
-
Patent number: 10864152Abstract: Described are methods and uses of TRPV3 agonists for the treatment of conditions associated with TRPV3 pathophysiology such as acne, psoriasis, dermatitis, would healing, the inhibition of hair growth, anxiety or depression. Peptides comprising all or part of the C-terminal portion of soricidin are shown to activate TRPV3 cation channel activity and/or promote wound healing in keratinocytes.Type: GrantFiled: September 14, 2017Date of Patent: December 15, 2020Assignee: Soricimed Biopharma Inc.Inventor: John M. Stewart
-
Patent number: 10618939Abstract: The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.Type: GrantFiled: March 14, 2018Date of Patent: April 14, 2020Assignee: The Hong Kong Polytechnic UniversityInventors: Yanxiang Zhao, Shuai Wu, Wenchao Yang, Yunjiao He, Xiaohua Li, Xianxiu Qiu
-
Patent number: 10513499Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.Type: GrantFiled: June 2, 2017Date of Patent: December 24, 2019Assignee: TES Pharma S.r.l.Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
-
Patent number: 10512651Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.Type: GrantFiled: August 21, 2015Date of Patent: December 24, 2019Assignee: STC.UNMInventor: Ellen Janine Beswick
-
Patent number: 10357481Abstract: The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: June 27, 2016Date of Patent: July 23, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Yili Chen, Michael P. Dwyer, Zack Zhiqiang Guo, Ming Wang, Shimin Xu, Yingjian Bo, Jianmin Fu
-
Patent number: 10281472Abstract: The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumor to eradicate, or slow or prevent tumor (5) growth and spread, including the potential for tumor metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.Type: GrantFiled: August 12, 2015Date of Patent: May 7, 2019Assignee: GILLIES MCINDOE RESEARCH INSTITUTEInventors: Ranui Francesca Baillie, Paul Frank Davis, Tinte Itinteang, Swee Thong Tan
-
Patent number: 10259848Abstract: The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized ?-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: GrantFiled: May 4, 2016Date of Patent: April 16, 2019Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory H. Bird
-
Patent number: 10227380Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: GrantFiled: January 29, 2015Date of Patent: March 12, 2019Assignee: AILERON THERAPEUTICS, INC.Inventors: Vincent Guerlavais, Christopher R. Conlee, Scott Paul Lentini
-
Patent number: 10221168Abstract: The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.Type: GrantFiled: February 16, 2016Date of Patent: March 5, 2019Inventor: Xiaohua Wu
-
Patent number: 10208000Abstract: Provided herein are novel small-molecules that have use in the inhibition of Eis, which mediates kanamycin resistance in Mycobacterium tuberculosis. The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as described herein, and a suitable pharmaceutical carrier. Methods of treating tuberculosis comprising administering to an individual an effective amount of the disclosed small molecule inhibitors to mediate kanamycin A resistance and treat tuberculosis are also provided.Type: GrantFiled: December 16, 2016Date of Patent: February 19, 2019Assignee: University of Kentucky Research FoundationInventors: Sylvie Garneau-Tsodikova, Oleg V. Tsodikov, James E. Posey
-
Patent number: 10150816Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.Type: GrantFiled: December 19, 2013Date of Patent: December 11, 2018Assignee: CELGENE CORPORATIONInventors: Stewart Abbot, Bitao Liang, Tianjian Li
-
Patent number: 10112948Abstract: The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.Type: GrantFiled: June 28, 2016Date of Patent: October 30, 2018Assignee: The Board of Regents of the University of Texas SystemInventors: Jef DeBrabander, Luis Parada
-
Patent number: 10093678Abstract: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.Type: GrantFiled: March 16, 2015Date of Patent: October 9, 2018Assignee: RaQualia Pharma Inc.Inventors: Yuji Shishido, Masashi Ohmi, Kazuo Ando
-
Patent number: 10058588Abstract: A protease resistant polypeptide includes an amino acid sequence that has a sequence identity at least 80% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1.Type: GrantFiled: May 23, 2017Date of Patent: August 28, 2018Assignee: Case Western Reserve UniversityInventors: Clark Distelhorst, Yiping Rong
-
Patent number: 9890197Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.Type: GrantFiled: July 23, 2015Date of Patent: February 13, 2018Assignee: London Health Sciences Centre Research Inc.Inventors: Leonard G. Luyt, Eva A. Turley, Kenneth Virgel Esguerra
-
Patent number: 9708267Abstract: Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer. A1-NR-L-A2(I).Type: GrantFiled: March 10, 2015Date of Patent: July 18, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Matthew B. Boxer, Min Shen, Douglas S. Auld, Craig J. Thomas, Martin J. Walsh
-
Patent number: 9682072Abstract: Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines. The compositions and methods may be useful for the treatment of an airway disorder such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), allergic disorders, pulmonary inflammatory diseases, pulmonary fibrosis, and/or interstitial lung diseases.Type: GrantFiled: October 10, 2016Date of Patent: June 20, 2017Assignee: Children's Hospital Medical CenterInventors: Vladimir Kalinichenko, Tatiana Kalin, Jeffrey A. Whitsett
-
Patent number: 9682980Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: June 19, 2013Date of Patent: June 20, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Ronald J. Mattson, Zhaoxing Meng, Leatte R. Guernon
-
Patent number: 9657031Abstract: ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrimidinone of formula I wherein R1 is —(CH2)n-CO—OH; —(CH2)n-CO—OR; —(CH2)n-CO—NHR; —(CH2)n-CO—N(R, R?); —(CH2)n-OH; —(CH2)n-OR; —(CH2)n-OAr; —(CH2)n-C(R,R?)—(CH2)n-OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.Type: GrantFiled: June 5, 2014Date of Patent: May 23, 2017Assignees: Universite de Versailles-Saint-Quentin-en-Yvelines, Center National de la Recherche Scientifique (CNRS), MitologicsInventors: Annie Borgne-Sanchez, Etienne Jacotot, Catherine Brenner
-
Patent number: 9657004Abstract: Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.Type: GrantFiled: August 26, 2015Date of Patent: May 23, 2017Assignee: AGIOS PHARMACEUTICALS, INCInventors: Francesco G. Salituro, Jeffrey O. Saunders
-
Patent number: 9605022Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.Type: GrantFiled: November 7, 2013Date of Patent: March 28, 2017Assignee: Ensemble Therapeutics CorporationInventors: Robert M. Borzilleri, Yong Zhang, Michael Miller, Andrew Fraley
-
Patent number: 9546176Abstract: Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided.Type: GrantFiled: November 20, 2013Date of Patent: January 17, 2017Assignee: DISCOVERYBIOMED, INC.Inventors: Erik Schwiebert, John Streiff, John Dixon, Hongwu Gao